MediciNovaMNOV -2.21%33 FCF Margin % is -1,861.50% as of Mar. 2026. GuruFocus rates MNOV with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, MediciNova ranks worse than 83.13% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MediciNova's Free Cash Flow for the
three
months ended in Mar. 2026 was $-3.48 Mil. MediciNova's Revenue for the
three
months ended in Mar. 2026 was $0.19 Mil. Therefore, MediciNova's FCF Margin % for the quarter that ended in Mar. 2026 was -1,861.50%.
The historical rank and industry rank for MediciNova's FCF Margin % or its related term are showing as below:
MNOV'
s FCF Margin % Range Over the Past 10 Years
Min: -2393.41 Med: -745.2 Max: -233.06
Current: -1592.46
During the past 13 years, the highest FCF Margin % of MediciNova was -233.06%. The lowest was -2393.41%. And the median was -745.20%.
MNOV's FCF Margin % is ranked worse than 83.13% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs MNOV: -1592.46
MediciNova FCF Margin % Related Terms
MediciNova FCF Margin % Historical Data
* Premium members only.
The historical data trend for MediciNova's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MediciNova's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediciNova FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediciNova's FCF Margin % distribution charts can be found below:
* The bar in red indicates where MediciNova's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediciNova (MNOV) has a FCF Margin % of -1,861.50% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MediciNova and its competitors. According to the industry distribution chart, MediciNova ranks #798 out of 960 companies in the Biotechnology industry, placing it in the top 83.1%.
Is MediciNova's FCF Margin % too high?
MediciNova's current FCF Margin % is -1,861.50%. Based on the distribution chart, MediciNova ranks #798 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MediciNova has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does MediciNova's FCF Margin % compare to ENTX and IMA?
According to the Biotechnology industry distribution chart, MediciNova ranks #798 out of 960 companies for FCF Margin %. This places MediciNova in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MediciNova and its competitors. MediciNova's current FCF Margin % is -1,861.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediciNova stock overvalued right now?
MediciNova (MNOV) has a current FCF Margin % of -1,861.50%. The current FCF Margin % is -1,861.50%. MediciNova's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For MediciNova (MNOV), the current FCF Margin % is -1,861.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
33GF Score
Get the complete analysis for MNOV
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNOV has been successfully added to your 
